- [18], proportional-integral-derivative control [19] , [20] , or fuzzy logic [21] , [22] have been proposed and tested in human trials. Additional control schemes have been tested in silico, e.g., H ∞ robust control design was employed in [23] [24] [25] , and by Parker et al., in [26] - [28] .
In particular, the subcutaneous-subcutaneous artificial pancreas (AP) scheme is considered here, where insulin delivery (control input) is performed by a continuous subcutaneous insulin infusion (CSII) pump, and glucose sensing (output measurement for feedback) is based on a CGM [3] . The difficulty is the large delay of both the subcutaneous sensing and actuation, in contrast to, e.g., intraperitoneal or intravenous alternatives. In response to hyperglycemic events, a long delay in the insulin action frequently causes a feedback controller to overdeliver insulin, inducing hypoglycemia-a condition that should be avoided. For a given control strategy, the solution to such controller-induced hypoglycemia is to detune the control law, making it to respond more conservatively throughout the controller operation. However, this typically leads to the elevated average glucose levels, and a sluggish return to a safe level following postprandial hyperglycemia.
Previous work by the authors was presented in [28] . There, a robust H ∞ controller with a so-called safety mechanism and insulin feedback loop reduced the risks of hyper-and hypoglycemia in T1DM. A time-varying controller that reproduces this H ∞ control structure, but in an linear parameter-varying (LPV) framework, was presented in [29] and achieved similar results. In this paper, we continue to pursue the LPV controller framework. The contribution of this paper is to consider a switched LPV controller that switches between a selection of multiple LPV controllers that individually have been designed for slightly different tasks (for another switched-LPV approach, see [30] ). Specifically, in this paper, the possibility of switching between only two LPV controllers is investigated, where one controller is dedicated to dealing with large and persistent hyperglycemic excursions, e.g., as occur after a meal, and the second controller is responsible for glucose control at all other times. The proposed strategy results in a controller that is conservative most of the time but switches into an "aggressive" mode when the need arises. In this paper, the "need" is based purely on CGM feedback, with no need of meal announcement, via an estimator that detects persistent high glucose values. This is akin to the proposal of Gondhalekar et al., [31] . However, the notion of switched LPV control can be expanded to other cases, e.g., for the controller to be triggered into a "meal" mode by means of an auxiliary meal-detection algorithm [32] , [33] , or by user notification. In this paper, simulation scenarios with only unannounced meals are investigated, as this is, in some sense, the most difficult case with respect to correcting hyperglycemia and preventing controller-induced hypoglycemia. Simulations are performed using the Food and Drug Administration (FDA) accepted UVA/Padova metabolic simulator [34] . This paper focuses on switching to improve the controller's response with respect to hyperglycemia. However, the proposed switching strategy is inherently flexible, and extensible to a variety of other scenarios also, e.g., in order to deal strategically with exercise. Analogously as with meal-related hyperglycemia, the proposed switching framework would allow us to design to handle hypoglycemia that typically follows exercise, by strategically including modes, e.g., where exercise is inferred from CGM trends, or through an auxiliary exercise detection mechanism, or by user input. However, the exercise component is not explicitly investigated in this paper because the FDA accepted UVA/Padova simulator currently has no means of simulating a person's exercise response.
This paper is organized as follows. Section II presents the controller design and analysis. Section III details the results obtained by testing the controller on the complete adult cohort of the UVA/Padova simulator. Conclusions and future research directions are discussed in Section IV.
II. METHODS
Two LPV controllers are designed for each in silico Adult #j of the complete UVA/Padova simulator: K i,j with i ∈ {1, 2}. Controller K 1,j is designed to control most of the time, while K 2,j is applied only when high and rising glucose values are estimated, e.g., after a meal. Because this strategy can estimate decreasing glucose values as well, perturbations like physical exercise may be detected and managed by another controller that was purposefully designed for such situations.
A. Patient Design Model
The model structure presented in [35] , and slightly adapted in [28] , is considered here to design both K 1,j and K 2,j . The main advantage of such a model structure is that it can be personalized based solely on a priori clinical information that can be easily obtained with high accuracy. Therefore, for each in silico Adult #j, the following individualized discrete-time transfer function G i,j (z) from the insulin delivery input (pmol/min) to the glucose concentration output (mg/dl) is defined:
where F i is a design factor (unitless) defined in (3) and (4), r j = 1800/TDI j , which is based on the 1800 rule [36] , adapts the model's gain to the total daily insulin (TDI) [U] of Adult #j (TDI j ), p 1 = 0.965, p 2 = 0.95, and p 3 = 0.93 are the poles, and the constant
is a constant that scales units and sets the correct gain. The factor F i is defined as follows:
where
with M j and CR j the body weight and the carbohydrate ratio, respectively, of Adult #j, and with M and CR, the mean population values based on the ten virtual adult patients of the distribution version of the UVA/Padova simulator. The decision to base the average values on the ten subject simulator's parameters was made in order not to overdesign with respect to the complete simulator. Instead, the TDI is readily and accurately obtainable from subjects, hence in that case, the value is based on the complete cohort of adults. The factor F 1 is defined to make a finer adjustment to the model's gain, including the effect of both M and CR. Thus, patients with low M and high CR are associated with an F 1 value greater than unity and, therefore, with a more conservative model. On the other hand, F 2 is intentionally smaller than F 1 in order to obtain a more aggressive control law when high and rising glucose levels are detected. However, according to the definition of F 2 , the more sensitive to insulin the patient, the higher the model gain and therefore, the less aggressive the control law. For example, if F 1 = 2, the model's gain is not reduced to design K 2,j .
B. Controller Design
In this paper, the MATLAB Robust Control Toolbox was used to compute the controllers. As that toolbox provides a solution only to the continuous-time LPV control synthesis problem, the discrete-time plant model G i,j (z) is converted to the continuous-time plant model G i,j (s) at the design stage. However, the desired control system operates in discrete time, therefore the derived continuous-time control law is converted to a discrete-time control law later, prior to implementation. The augmented continuous-time model for controller design is depicted in Fig. 1 , where r and e are, respectively, the reference and error signals, u is the control action, and W u,i and W p,i (s) are the design weights.
As shown in Fig. 1 , two parameters have been included in each augmented model in order to adapt the controller during the closed-loop implementation. The time-varying parameters are
and θ 2 (t) =
. The first parameter is realtime measurable and depends on the glucose level g(t) measured by the CGM. The second parameter depends on [i pe (t), i pb ], which are the estimated current and basal plasma insulin levels, respectively. The estimation is performed through the subcutaneous insulin model proposed in [37] , considering its mean population values. In the case of i pe (t), the input to the model is the current injected insulin, and in the case of i pb , the basal insulin dosage. Note that i pb can be obtained offline before the simulation.
In order to design both LPV controllers, the performance and actuator weights are defined as follows:
with
is linear in the time-varying parameters; therefore, as they increase, W u,i forces a less aggressive control. According to these parameters, both design weights related to K 2,j are defined slightly less conservatively than those related to K 1,j . The weight W p,i (s) is chosen to be a low-pass filter to induce fast tracking of the safe blood glucose levels. On the other hand, note that in the case of time invariant θ 1 (t) = θ 1 (0) = θ 10 and θ 2 
is linear time invariant (LTI) and resembles a derivative at low frequencies. Therefore, it helps to penalize fast changes in the insulin delivery. In addition, the model is strictly proper, in order to have the closed-loop system affine in the time-varying parameters.
The parameter
T is constrained to lie within the rectangular sets
and K 2,j , respectively. Therefore, both sets P 1 and P 2 , which are depicted in Fig. 2 , have v = 4 vertices. The lower and upper bounds of the set P 1 are related to the expected minimum and maximum values of the corresponding variables g(t) and i pe (t), i.e., 20 ≤ g(t) ≤ 550 mg/dl and i pe (t) from 0 to 8 times its basal value. Note that in the case of the set P 2 , the maximum value of θ 1 (t) is unity, i.e., g(t) = 110 mg/dl. As will be shown in Section II-D, that value corresponds to the glucose threshold used by the switching signal algorithm to detect the hyperglycemia condition. An increase in θ 1 (t) due to a low glucose level and/or in θ 2 (t) due to a high level of insulin on board (IOB) reduces fast and aggressive increases in insulin injection. As the augmented open-loop model matrices [see Fig. 1 and (7) and (8)] depend affinely on the parameter θ(t) = [θ 1 (t), θ 2 
(t)]
T , and that the parameter regions are convex polytopes with a finite number of vertices (see Fig. 2 ), the optimization problem related to the LPV controller synthesis can be stated in terms of a finite number of linear matrix inequalities (LMIs). Specifically, for each LPV controller, the problem is solved in terms of 2v + 1 LMIs, i.e., a common single quadratic Lyapunov function (SQLF) for each set of v = 4 vertices. Note that the vertex controllers can be synthesized offline.
During the implementation phase, the two LPV controllers for i = 1, 2 can be computed as follows:
where η (t) ≥ 0 ∀t ∈ [0, ∞) are the polytopic coordinates of the measured parameter θ(t), and θ i, are the vertices of P i .
One of the problems of the LPV control is known as the "fast poles" problem. By "freezing" any point in the parameter variation set, the resulting LTI model usually presents a small number of poles with a small (i.e., large negative) real part [38] , [39] . Fast poles lead to problems from the practical point of view, e.g., integration and/or implementation becomes difficult with these fast dynamics. The approach utilized to deal with these difficulties is LPV pole placement [39] . Through LMI constraints, the objective of the LPV pole placement is to keep the poles of each LTI closed-loop system, resulting from holding the parameter fixed at each point of the parameter variation set, in a prescribed region of the complex plane. Therefore, in order to solve numerical issues in the implementation and/or simulation, for each LPV controller, the (continuous-time) closed-loop poles are constrained to the region D = q ∈ C : − 2π 100 < Re(q) < 0 , i.e., at least ten times slower than the controller sampling time T s = 10 min. This pole-placement region forces the closed-loop (frozen) poles not to be faster than 1 × 10 −3 rd/s in order to obtain a closed-loop response as fast as possible for meal perturbation, but also taking into account that the achievable closed-loop bandwidth is limited since insulin cannot be removed in case of overdelivery [35] .
Before implementation, each polytopic LPV controller is converted to a representation which is affine in the time-varying parameters. Finally, a trapezoidal LPV state-space discretization is applied at the implementation stage (see [40, pp. 143-169] ).
C. Stability and Performance Analysis
Note that the design was performed by computing a SQLF for each controller. In order to guarantee closed-loop stability and performance under arbitrary switching among controllers, a common SQLF is sought for both LPV controllers [41] . The block diagram of the closed-loop is depicted in Fig 3, where
Only G 1,j (s) is considered in the analysis because it represents the "real" transfer function (G 2,j (s) is a fictitious system) and, therefore, describes the patient's glucose-insulin dynamics more accurately.
To proceed, the following arguments will be used:
1) The dependence of the state space matrices
] of both LPV controllers on the parameter θ(t) is affine. 2) From (8), only the output matrix C u,i of W u,i is a function of θ(t). As a consequence, after tedious but straightforward algebra (see appendix for the details), the linear fractional interconnection between L j (s) and the controllers K i,j as depicted in Fig. 3 produce the following closed-loop state-space matrices that are also affine in the parameter θ(t):
Therefore, each affine LPV system can be completely defined by the vertex systems [42] , i.e., the images of the v vertices that make up each parameter set P i , with i = 1, 2. In this way, the problem consists in seeking, for each Adult #j, a symmetric and positive-definite matrix X j ∈ R n ×n , with n the number of closed-loop states, that satisfies the following 2v + 1 LMIs: By solving one such set of 2v + 1 LMIs for each patient, the existence of such matrices proved switching stability and performance in all cases. Due to the fact that a more restrictive condition is sought with respect to the design stage, the performance index γ is 30% higher on average for all patients. In any case, this is only a necessary condition, because the final test is performed on the complete adult cohort of the UVA/Padova metabolic simulator in Section III. 
D. Switching Signal
As mentioned above, K 2,j is applied only when high and rising glucose values are detected, e.g., after a meal. The block diagram associated with the generation of the switching signal that commands which LPV controller is selected is depicted in Fig. 4 . Because of the high measurement noise, some unrealistic hyperglycemic conditions may be detected. Therefore, in order to reduce the number of such false positive detections, the following algorithm, which is similar to the one presented in [33] , is defined. The glucose measured by the CGM is filtered by a noise-spike filter (NSF), setting to 3 mg/dl/min the maximum allowable glucose rate of change (ROC) [43] . Then, g f (t) is filtered by a fourth-order Savitzky-Golay filter (SGF) [44] to estimate the glucose ROC denoted byĝ(t). If g f (t) is higher than 110 mg/dl, and if the last three estimated glucose ROC values are higher than 1.2 mg/dl/min or the last two are higher than 1.4 mg/dl/min, the signal h d (t), which is zero by default, is set to unity by the hyperglycemia detector (HD) block. When the latter condition is no longer met, h d (t) is reset to zero. In addition, in order to create a more robust system against the CGM measurement noise, it is considered that h d (t) can be set to unity only if the time period from the last falling edge to the new detection is longer than 30 min. The evolution of the index i that indicates which controller K i,j is applied is described by a continuous-time function σ(t) ∈ {1, 2}. The variablesĝ(t) and h d (t) are inputs to the switching signal generator (SSG) block to define σ(t) as follows. The sampling time after h d (t) is set to unity, σ(t) is set to two whenĝ(t) ≥ 1 mg/dl/min. Thus, if σ(t) = 2, K 2,j is selected untilĝ(t) < 1 mg/dl/min, consequently guaranteeing that θ(t) ∈ P 2 while σ(t) = 2.
III. RESULTS
All in silico adults of the complete UVA/Padova metabolic simulator are considered for simulations, using CGM as the sensor, a generic CSII pump, and with unannounced meals.
The two protocols (see Table I ) and the same simulation and analysis conditions used in [28] are employed for controller performance comparison. Note that protocol #1 has a fairly high meal content, whereas protocol #2 has fasting periods. Thus, 1) The fasting state of each subject is assumed at the start of the simulation. 2) Open-loop control that infuses the basal insulin is applied during the first 4 h. After that, the switched LPV controller takes over the insulin delivery until the end of the simulation, with a constant setpoint of 110 mg/dl. 3) A postprandial period (PP) and night (N) are defined as the 5-h-time interval following the start of a meal, and the period from midnight to 7:00 A.M., respectively. In [28] , both the control variability grid analysis (CVGA) plot [45] as well as the average results are computed based on the results of the third day for protocol #1, and based on the data from the second day for protocol #2. Therefore, to facilitate a direct comparison with the control strategy proposed in [28] , in this paper, we adopt the same analysis strategy to interpret the results. During the implementation phase, the control action u(t) added to the basal insulin i b = I b,j is delivered by the CSII pump. In order to avoid dangerous scenarios, when σ(t) = 1, g f (t) < 130 mg/dl, andĝ(t) < −0.3 mg/dl/min, the basal insulin is reduced 25%, i.e., i b = 0.75I b,j . Based on the small gain theorem [46] , the latter does not affect the closed-loop stability. Fig. 6 . CVGA plots of the closed-loop responses of all in silico subjects (complete UVA/Padova simulator) for the proposed switched-LPV control (stars) and the previous H ∞ approach (circles) with respect to protocol #1 (left) and protocol #2 (right). The CVGA categories represent different levels of glucose control, as follows: accurate (A-zone), benign deviation into hypo/hyperglycemia (lower/upper B-zones), benign control (B-zone), overcorrection of hypo/hyperglycemia (upper/lower C-zone), failure to manage hypo/hyperglycemia (lower/upper D-zone), and erroneous control (E-zone). See Table II for zone inclusion percentages. The overall (O), and the PP and N time intervals defined previously are analyzed separately.
The average time responses to both protocols are depicted in Fig. 5 . The CVGA plots and the average results related to both protocols are presented in Fig. 6 and Table II, respectively. Results for the H ∞ approach presented in [28] are also included in Fig. 6 and Table II for comparison. Note that the risk of hyperglycemia is substantially reduced, obtaining a high blood glucose index (HBGI) < 3 with this proposed approach (PA). For example, the mean blood glucose is about 15 mg/dl lower, and the percentage of time in the range [70, 180] mg/dl is approximately 25% higher with this approach than with the H ∞ one. As a result of this more aggressive tuning, the CVGA plots are shifted to the right but the risk of hypoglycemia is scarcely increased, achieving a minimal low blood glucose index (LBGI < 1.1). Although a few more subjects are in the D-zone, it is not a problem if that implies an improvement in the general patient population. This is the case because this virtual patient database should be evaluated as a whole population covering different behaviors, and not as individuals. In addition, a more aggressive control action also increases the TDI but again, with no significant increase in the risk of hypoglycemia. Finally, it is worth noting that most of the closed-loop responses are in the upper B-zone. The main reason for that situation is that meals are unannounced, and therefore, blood glucose peaks after meals are difficult to prevent [28] , [35] , [47] .
In order to show how the switching system works, an individual closed-loop response to protocol #1 is presented in Fig. 7 . As shown in that figure, when K 2,j is selected (σ(t) = 2), insulin delivery experiences spikes, reducing postprandial glucose levels. The delay between meal ingestion and controller switching is mainly related to the long sensing delays. In addition, it is well known that high measurement noise appears when CGM is used as the sensor. Despite the noisy CGM signal as depicted in Fig. 8 , the controller manages to maintain the blood glucose at a safe level.
The variation of θ(t) = [θ 1 (t), θ 2 (t)] T is depicted in Fig. 9 . Note that there is a gray narrow stripe around θ 1 (t) = 1 and 0 ≤ θ 2 (t) ≤ 1 because θ 2 (0) = 0, but this subsequently increases until the estimated plasma insulin converges to its steady-state value. As shown in Fig. 9 , both parameters evolve within a safe region. This means that when the blood glucose level decreases (θ 1 (t) increases), the plasma insulin level decreases (θ 2 (t) decreases), avoiding an overdose of insulin. On the other hand, when the blood glucose level increases (θ 1 (t) decreases), so does the plasma insulin level (θ 2 (t) increases), reducing in this way the risk of hyperglycemia. Consequently, dangerous scenarios like low blood glucose values and high plasma insulin levels or vice versa do not occur with this switched LPV approach. Furthermore, the darkest area, which represents the region where both parameters spend the highest percentage of time, is (θ 1 , θ 2 ) (1, 1). This means that glucose values are usually around the setpoint (110 mg/dl) without high levels of IOB, despite perturbations like unannounced meals.
Although for the design stage both parameters are included in a rectangular region that is larger than the region where the actual time-varying parameters evolve, this conservative choice is necessary in order to have stability and performance guarantees when this is not the case, e.g., due to a large measurement error.
IV. CONCLUSION
A general switched-LPV controller was designed in order to minimize risks of hyper-and hypoglycemia. This control structure naturally accommodates the time-varying/nonlinear dynamics and intrapatient uncertainty. The controller is based on a model tuned with the patient a priori information in order to cover the interpatient uncertainty. Finally, a hyperglycemia estimator is used to predict perturbations, e.g., risky PPs. The outcome is an improvement on previous results. The key feature is the possibility of taking into account, at the design stage, important perturbations: unannounced meals and/or patient's physical exercise. Here, we have explored the first situation, due to the fact that the UVA/Padova simulator has no physical exercise model. Nevertheless, the same procedure could be applied to the latter situation by either estimating a negative ROC in glucose levels, or through a real-time measurement, e.g., increase in cardiac rhythm.
APPENDIX INTERCONNECTION BETWEEN L j (s) AND K i,j
Consider that the performance and actuator weights are given by Hence, the linear fractional interconnection between L j (s) and the corresponding LPV controller
yields the closed-loop matrices (13)- (16) , which are affine in θ(t).
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